Terazocin HCl

α1- and α2B-adrenoceptor antagonist (Ki = 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α1A, α1B, α1D, α2B, α2A and α2C receptors respectively) 1. Displays antihypertensive activity2. Improves glucose and lipid metabolism in hypertensives3. Displays antiangiogenic activity in human prostate cancer and endothelial cells4. Activates Pgk1 and Hsp90 to promote stress resistance5. Active in vivo.